We’ve scanned the newsfeeds of all the important marijuana stocks and put together this recap so you don’t have to.
Top News Stories for Wednesday, September 18, 2019:
Curaleaf (CSE: CURA) (OTCQX: CURLF) announced the opening of its seventh dispensary in Arizona today.
The new dispensary is located at 2175 N 83rd Avenue in the Phoenix metro area.
Auxly Cannabis (TSXV: XLY) (OTCQX: CBWTF) announced it has entered into a brokerage agreement with Kindred Partners for the purpose of Kindred acting as Auxly’s exclusive sales agent for its recreational cannabis products in Canada.
“Having Kindred as our sales and brokerage partner is a fantastic complement to the strong relationships that we continue to build with the provincial boards and accelerates our vision of becoming a leader in the derivative cannabis product market,” said Auxly Head of Commercial Jeff O’Neill.
Zenabis Global (TSX: ZENA) (OTCPK: ZBISF) released an update on its new facility construction, licensing activities and recent cannabis production results.
A few of the highlights included:
- August 2019 cultivation output of 1,996 kg of dried cannabis.
- Dried cannabis output was 26.4% higher than the company’s revised forecast.
Flower One (CSE: FONE) (OTCQX: FLOOF) announced one of its subsidiaries has signed a sale-leaseback agreement with Treehouse Real Estate Investment Trust.
The deal was signed for the company’s 25,000 sq ft indoor cultivation and production facility located in North Las Vegas and includes the adjacent vacant lot acquired early in 2019.
1933 Industries (CSE: TGIF) (OTCQX: TGIFF) announced an exclusive licensing deal between its subsidiary, Alternative Medicine Association (AMA) and HH Global for the intellectual property rights to The Original Jack Herer® brand of cannabis products in Nevada for a term of one-year.
As per the terms of the deal, AMA will license, market and distribute The Original Jack Herer® flower, pre-rolls, vape cartridges and concentrates to the Nevada market.
Halo Labs (NEO: HALO) (OTCQX: AGEEF) announced it has entered into an unsecured debt financing agreement with a private arm’s-length lender for up to $10,000,000 CDN.
Halo will take an initial draw of $1,000,000 CDN for working capital and raw material in California.
Zynerba Pharmaceuticals (NASDAQ: ZYNE) announced positive top-line results from its open-label Phase 2 BELIEVE 1 Open-Label Study.
The purpose of the study was to assess the safety and efficacy of Zygel™ (ZYN002) when administered as a transdermal gel to children and adolescents with Developmental and Epileptic Encephalopathy.
Move Over Curaleaf, There’s a New MSO in Town and it’s Set to Hit The Street This September
Get the full details here so you don’t miss out on the next potential 10 bagger.